To further elucidate the interactions and potential mechanisms between CEP and four key targets (AKT1, EGFR, SRC, and FN1) in the treatment of BPH, we performed comprehensive molecular docking simulations. The gene discussed is AKT1; the disease is benign prostatic hyperplasia.